DAMOTRIM

This brand name is authorized in Nigeria.

Active ingredients

The drug DAMOTRIM contains a combination of these active pharmaceutical ingredients (APIs):

1	Sulfamethoxazole UNII JE42381TNV - SULFAMETHOXAZOLE
	Sulfamethoxazole competitively inhibits the utilisation of para-aminobenzoic acid in the synthesis of dihydrofolate by the bacterial cell resulting in bacteriostasis.
	Read more about Sulfamethoxazole
2	Trimethoprim UNII AN164J8Y0X - TRIMETHOPRIM
	Trimethoprim is a dihydrofolate reductase inhibitor, inhibiting the conversion of bacterial dihydrofolic acid to tetrahydrofolic acid, required for the synthesis of some amino acids. Its effects are considerably greater on the cells of micro-organisms than on the mammalian cells.
	Read more about Trimethoprim

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A11-1056	Tablet	DAMOTRIM TABLET TAB 400 mg; 80 mg 10 x 10	DAMOTRIM TABLET Damotrim Sulphamethoxazole, Trimethoprim Antibiotics Sulphamethoxazole 400mg, Trimethoprim 80mg Tablet 10 x 10 Treatment of infections caused by susceptible Organisms POM Danax Nigeria Limited (Pharm Division) 59/61, Akinwunmi Kosemani Street, Idimu, Lagos Fidson Healthcare PLC KM 38, Lagos-Abeokuta Expressway, Sango-Ota Ogun State " LR - SATIS 27/08/18 GMP - satis " 05/04/2018 A11 - 1056	30/01/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01EE01	Sulfamethoxazole and trimethoprim	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01E Sulfonamides and trimethoprim → J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives
Discover more medicines within J01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A11-1056